Sarepta Therapeutics Inc. held its annual meeting of stockholders on June 5, 2025. During the meeting, several proposals were voted upon. The election of directors resulted in Richard J. Barry, M. Kathleen Behrens, Ph.D., Stephen L. Mayo, Ph.D., and Claude Nicaise, M.D. being elected to the board. An amendment to the 2018 Equity Incentive Plan was approved, increasing the maximum aggregate number of shares of common stock that may be issued. An amendment to the Amended and Restated 2013 Employee Stock Purchase Plan was also approved. Additionally, the ratification of KPMG as the Company's Independent Registered Public Accounting Firm was confirmed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.